Skip to main content

Table 1 Subject randomization

From: A randomized, double blind, placebo and active comparator controlled pilot study of UP446, a novel dual pathway inhibitor anti-inflammatory agent of botanical origin

Group

Name

Sample size

Compound

Dosage

A 0

Placebo

n = 15

Placebo

N/A (CMC capsule b.i.d)

A 1

Dose 1

n = 15

UP446

250 mg/day (125 mg b.i.d.)

A 2

Dose 2

n = 15

UP446

500 mg/day (250 mg b.i.d.)

A 3

Dose 3

n = 15

Celecoxib

200 mg/day (100 mg b.i.d.)

  1. Acetaminophen was provided as rescue medication. Subjects were permitted to take up to 1000 mg t.i.d.
Back to article page

Nutrition Journal

ISSN: 1475-2891

Contact us